Malignant mucosal melanoma of the head and neck

Pathology and Oncology Research

Volumn 9, Issue 1, 2003, Pages 7-12

  Lengyel, Erzsébet ^a   Gilde, Katalin ^a   Remenár, Éva ^a   Ésik, Olga ^a,b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Chemotherapy; Head and neck; Malignant melanoma; Mucosal melanoma; Radiotherapy; Surgery

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BCG VACCINE; CARMUSTINE; CISPLATIN; CYSTEINYLDOPA; DACARBAZINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MELAN A; MELPHALAN; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; PROTEIN S 100; TAMOXIFEN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; MELANOMA; METASTASIS; MOUTH CANCER; PHARYNX CANCER; REVIEW; SEX DIFFERENCE; SURVIVAL RATE; UPPER RESPIRATORY TRACT;

EID: 0037570891     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033707     Document Type: Review

References (53)

1. Agarwala SS, Atkins MB, Kirkwood JM: Current approaches to advanced and high-risk melanoma. Proc Am Soc Clin Oncol 2000.
2. Ang KK, Byers RM, Peters LJ, et al: Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Arch Otolaryngol Head Neck Surg 116:169-172, 1990.
3. Bánfalvi T, Boldizsár M, Gergye M, et al: Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8:183-187, 2002.
4. Barranco SC, Romsdahl MM, Humphrey RM: The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31:830-831, 1971.
5. Barton RT: Mucosal melanomas of the head and neck. Laryngoscope 85:93-99, 1975.
6. Batsakis JD, Regezi JA, Solomon AR, et al: The pathology of head and neck tumors-part 13: mucosal melanomas. Head Neck Surg 4:404-412, 1982.
7. Berking C, Schlüpen E, Schrader A, et al: Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminometric assay for S-100. Arch Dermatol Res 291:479-484, 1999.
8. Blatchford SJ, Koopman CF, Coulthard SW: Mucosal melanoma of the head and neck. Laryngoscope 96:929-934, 1986.
9. Brandwein MS, Rothstein A, Lawson W, et al: A clinicopathologic study of 25 cases and literature meta-analysis. Arch Otolaryngol Head Neck Surg 123:290-296, 1997.
10. Britten CD, Rowinsky EK, Baker SD, et al: A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629, 1999.
11. Chang AE, Karnell LH, Menck HR: The National Cancer Data Base Report on cutaneous and noncutaneous melanoma. Cancer 83:1664-1678, 1998.
12. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745, 1999.
13. Chaundhry AP, Hampel A, Gorlin RJ: Primary melanoma of the oral cavity. Cancer 11:923-928, 1958.
14. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516, 1992.
15. Eneroth CM, Lungberg C: Mucosal malignant melanomas of the head and neck. Acta Otolaryngol 80:452-458, 1975.
16. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403, 1991.
17. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon -2b versus dacarbazine with interferon -2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study (E3690). J Clin Oncol 16:1743, 1998.
18. Freedman HM, DeSanto LW, Devine KD, et al: Malignant melanoma of the nasal cavity and paranasal sinuses. Arch Otolaryngol 97:322-325, 1973.
19. Gilligan D, Slevin NJ: Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 64:1147-1150, 1991.
20. th ed, Lippincott Williams and Wilkins, Philadelphia-Baltimore-New York-London-Buenos Aires-Hong Kong-Sydney-Tokyo, 2001, pp. 2537-2569.
21. Goldman JA, Lawson W, Zak FG, et al: The presence of melanocytes in human larynx. Laryngoscope 82:824-835, 1972
22. Gotshalk HC, Tessmer CF, Smith JW: Malignant melanoma of palate. Arch Pathol 30:762, 1940.
23. Guzzo M, Grandi C, Licitra L, et al: Mucosal malignant melanoma of head and neck: forty-eight cases treated at Instituto Nazionale Tumori of Milan. Eur J Surg Oncol 19:316-319, 1993.
24. th ed. Philadelphia: Lippincott-Williams and Wilkins, 2000.
25. Harrison DFN, Lund VJ: Tumors of the upper jaw. Edinburgh, London: Churchill Livingstone, 1993, pp. 332.
26. Keilholz U, Eggermont AM: The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. Canc J Scient Am 6:S99, 2000.
27. Kingdom TT, Kaplan MJ: Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck 17:184-189, 1995.
28. Lange JR, Raubitschek AA, Pockaj BA, et al: A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother 12:265, 1992.
29. Lattanzi SC, Tosteson T, Chertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow up. Melanoma Res 5:365, ref 1995.
30. Lee SP, Shimizu KT, Tran LM, et al: Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 104:121-126, 1994.
31. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752, 1998.
32. Liversedge RL: Oral malignant melanoma. Br J Oral Surg 13:40-55, 1975.
33. th ed, Lippincott Williams and Wilkins, Philadelphia-Baltimore-New York-London-Buenos Aires-Hong Kong-Sydney-Tokyo, 2001, 2012-2069.
34. Lund VJ: Malignant melanoma of the nasal cavity and paranasal sinuses. J Laryngol Otol 96:347-355, 1982.
35. Lund VJ: Malignant melanoma of the nasal cavity and paranasal sinuses. ENT J 72:285-290, 1993.
36. Lund VJ, Howard DJ, Harding L, et al: Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 109:208-211, 1999.
37. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000.
38. Pandey M, Mathew A, Iype EM, et al: Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature. Eur J Cancer Prevention 11:3-10, 2002.
39. Patel SG, Prasad ML, Escrig M et al: Primary mucosal malignant melanoma of the head and neck. Head Neck 24:247-257, 2002.
40. rd ed, Philadelphia-New York: Lippincott-Raven, 1997, pp. 1122-1123.
41. Rinaldo A, Shaha AR, Patel SG, et al: Primary mucosal melanoma of the nasal cavity and paranasal sinuses. Acta Otolaryngol 121:979-982, 2001.
42. Rosenberg Sa, Yanelli Jr, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159-1166, 1994.
43. Rosenberg SA, White DE: Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immuntherapy. Journal of Immuntherapy with Emphasis on Tumor Immunology 19:81, 1996.
44. Rosenberg Sa, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999.
45. Shah JP, Huvos AG, Strog EW: Mucosal melanomas of the head and neck. Am J Surg 134:531-535, 1977.
46. Shibuya H, Takeda M, Matsumoto S, et al: The efficacy of radiation therapy for malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys 25:35-39, 1992.
47. Stern SJ, Guillamondegui OM: Mucosal melanoma of the head and neck. Head Neck 13:22-27, 1991.
48. Tagliaferri P, Barile C, Caraglia M, et al: Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. Am J Clin Oncol 21:48-53, 1998.
49. Takagi M, Ishikawa G, Mori W: Primary malignant melanoma of the oral cavity in Japan. Cancer 34:358, 1974.
50. Timár J, Csuka O, Orosz Z, et al: Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res 7:217-230, 2001.
51. Trapp TK, Fu Y-S, Calcaterra TC: Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol Head Neck Surg 113:1086-1089, 1987.
52. Trott KR, von Lieven H, Kummermehr J, Skopal D, et al: The radiosensitivity of malignant melanomas. Part I: Experimental studies. Int J Radiat Oncol Biol Phys 7:9-13, 1981.
53. Trott KR, von Lieven H, Kummermehr J, et al. Radiosensitivity of malignant melanomas. Part II: Clinical studies. Int J Radiat Oncol Biol Phys 7:15-20, 1981.